Marianna Mancini
Known title: Chief Operating OfficerCIK: 0001838112
Associated companies
Transaction History
| VKTX | ▼ Sell | Open Market | 18,217 | $610K | 7/29/2026 | View on chart |
| VKTX | ▲ Buy | Grant | 31,667 | $0 | 7/28/2026 | View on chart |
| VKTX | ▼ Sell | Open Market | 31,961 | $1.0M | 1/5/2026 | View on chart |
| VKTX | ▼ Sell | Open Market | 13,600 | $454K | 1/5/2026 | View on chart |
| VKTX | ▼ Sell | Open Market | 10,500 | $359K | 1/5/2026 | View on chart |
| VKTX | ▼ Sell | Open Market | 1,600 | $56K | 1/5/2026 | View on chart |
| VKTX | ▲ Buy | Grant | 41,000 | $0 | 1/2/2026 | View on chart |
| VKTX | ▲ Buy | Grant | 32,049 | $0 | 1/2/2026 | View on chart |
| VKTX | ▼ Sell | Open Market | 6,185 | $216K | 10/28/2025 | View on chart |
| VKTX | ▲ Buy | Grant | 11,117 | $0 | 10/27/2025 | View on chart |
| VKTX | ▼ Sell | Open Market | 4,266 | $118K | 7/3/2025 | View on chart |
| VKTX | ▲ Buy | Grant | 7,667 | $0 | 7/2/2025 | View on chart |
| VKTX | ▼ Sell | Open Market | 49,115 | $2.1M | 1/6/2025 | View on chart |
| VKTX | ▼ Sell | Open Market | 5,100 | $221K | 1/6/2025 | View on chart |
| VKTX | ▲ Buy | Grant | 44,533 | $0 | 1/3/2025 | View on chart |
| VKTX | ▲ Buy | Grant | 21,667 | $0 | 1/3/2025 | View on chart |
| VKTX | ▼ Sell | Open Market | 14,704 | $838K | 7/30/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 3,322 | $192K | 7/30/2024 | View on chart |
| VKTX | ▲ Buy | Grant | 21,667 | $0 | 7/29/2024 | View on chart |
| VKTX | ▲ Buy | Grant | 10,000 | $0 | 7/29/2024 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 17,999 | $84K | 5/1/2024 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 87,000 | $425K | 5/1/2024 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 90,000 | $522K | 5/1/2024 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 35,426 | $275K | 5/1/2024 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 51,000 | $435K | 5/1/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 23,746 | $1.8M | 5/1/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 26,142 | $2.0M | 5/1/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 105,343 | $8.3M | 5/1/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 119,946 | $9.5M | 5/1/2024 | View on chart |
| VKTX | ▼ Sell | Open Market | 6,248 | $500K | 5/1/2024 | View on chart |
| VKTX | ▲ Buy | Grant | 31,667 | $0 | 3/27/2024 | View on chart |
| VKTX | ▼ Sell | Tax Withholding | 16,610 | $1.4M | 3/27/2024 | View on chart |
| VKTX | ▼ Sell | Tax Withholding | 16,958 | $1.4M | 3/1/2024 | View on chart |
| VKTX | ▲ Buy | Grant | 31,667 | $0 | 3/1/2024 | View on chart |
| VKTX | ▼ Sell | Tax Withholding | 14,199 | $264K | 1/4/2024 | View on chart |
| VKTX | ▲ Buy | Grant | 28,334 | $0 | 1/3/2024 | View on chart |
| VKTX | ▼ Sell | Tax Withholding | 16,533 | $288K | 1/3/2024 | View on chart |
| VKTX | ▲ Buy | Grant | 70,000 | $0 | 1/3/2024 | View on chart |
| VKTX | ▼ Sell | Tax Withholding | 32,677 | $569K | 1/3/2024 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 12,500 | $163K | 4/17/2023 | View on chart |
| VKTX | ▼ Sell | Open Market | 12,500 | $250K | 4/17/2023 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 36,100 | $614K | 3/30/2023 | View on chart |
| VKTX | ▼ Sell | Tax Withholding | 30,799 | $541K | 3/30/2023 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 23,100 | $197K | 3/30/2023 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 10,000 | $77K | 3/30/2023 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 3,000 | $19K | 3/30/2023 | View on chart |
| VKTX | ▲ Buy | Grant | 56,667 | $0 | 3/30/2023 | View on chart |
| VKTX | ▼ Sell | Open Market | 41,242 | $660K | 3/29/2023 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 15,000 | $137K | 3/29/2023 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 15,000 | $32K | 3/28/2023 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 4,873 | $9K | 3/28/2023 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 15,000 | $16K | 3/28/2023 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 24,500 | $114K | 3/28/2023 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 30,000 | $131K | 3/28/2023 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 15,000 | $19K | 3/28/2023 | View on chart |
| VKTX | ▼ Sell | Open Market | 196,563 | $2.9M | 3/28/2023 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 53,054 | $65K | 3/28/2023 | View on chart |
| VKTX | ▲ Buy | Option Exercise | 10,000 | $10K | 3/28/2023 | View on chart |
| VKTX | ▼ Sell | Tax Withholding | 1,079 | $10K | 1/15/2023 | View on chart |
| VKTX | ▼ Sell | Tax Withholding | 13,994 | $118K | 1/4/2023 | View on chart |
| VKTX | ▼ Sell | Tax Withholding | 18,854 | $161K | 1/3/2023 | View on chart |
| VKTX | ▲ Buy | Grant | 90,667 | $0 | 1/3/2023 | View on chart |
| VKTX | ▼ Sell | Tax Withholding | 12,773 | $120K | 12/30/2022 | View on chart |
| VKTX | ▲ Buy | Grant | 23,500 | $0 | 12/30/2022 | View on chart |
| VKTX | ▼ Sell | Tax Withholding | 827 | $4K | 1/15/2022 | View on chart |
| VKTX | ▼ Sell | Tax Withholding | 11,845 | $55K | 1/4/2022 | View on chart |
| VKTX | ▼ Sell | Tax Withholding | 3,919 | $19K | 1/3/2022 | View on chart |
| VKTX | ▲ Buy | Grant | 77,333 | $0 | 1/3/2022 | View on chart |
| VKTX | ▲ Buy | Grant | 6,667 | $0 | 9/28/2021 | View on chart |
| VKTX | ▼ Sell | Tax Withholding | 2,839 | $18K | 9/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Viking Therapeutics Launches New Oral Obesity Study
Viking Therapeutics announced a new oral maintenance study for its obesity program, a key step in its drug development pipeline. This news comes as the stock has fallen over 30% in the last three months, trading near its 52-week low. While an analyst recently maintained a buy rating with a lowered price target, the broader market view remains mixed given the recent price decline.
Viking Therapeutics Launches New Oral Obesity Study. Viking Therapeutics announced a new oral maintenance study for its obesity program, a key step in its drug development pipeline. This news comes as the stock has fallen over 30% in the last three months, trading near its 52-week low. While an analyst recently maintained a buy rating with a lowered price target, the broader market view remains mixed given the recent price decline.